

**Minutes of the meeting of the AREA PRESCRIBING COMMITTEE held on  
Wednesday 12<sup>th</sup> October 2016 in the Boardroom at Hillder House**

**MEMBERS:**

Dr M Ghani (Chair)	Medical Director (Barnsley CCG)
Mr T Bisset	Community Pharmacist (LPC)
Ms S Hudson	Lead Pharmacist (SWYPFT)
Dr K Kapur (for item 16/186&188 only)	Consultant Gastroenterology (BHNFT)
Ms C Lawson	Head of Medicines Optimisation (Barnsley CCG)
Dr J Maters	General Practitioner (LMC)
Dr A Munzar	General Practitioner (LMC)
Mr M Smith	Chief Pharmacist (BHNFT)

**ATTENDEES:**

Ms C Applebee	Medicines Management Pharmacist (Barnsley CCG)
Ms N Brazier	Administration Officer (Barnsley CCG)
Mr N Heslop	Lead Pharmacist (Barnsley CCG)
Mr F Hussain	Senior Interface Pharmacist (BHNFT)
Dr D Kerrin (for item 16/188 only)	Consultant Paediatrician and Allergy Lead (BHNFT)
Mr U Patel	Clinical Pharmacist (BHNFT)
Ms G Turrell	Lead Pharmacist, Medicines Information (BHNFT)

**APOLOGIES:**

Dr R Hirst	Palliative Care Consultant (Barnsley Hospice)
Dr R Jenkins	Medical Director (BHNFT)
Dr K Sands	Associate Medical Director (SWYPFT)

**ACTION BY  
AND  
DEADLINE**

**APC 16/184 QUORACY** – the meeting was quorate.

**APC 16/185 DECLARATIONS OF INTEREST RELEVANT TO THE AGENDA**

There was one declaration of interest to note from Dr Kerrin who was in attendance for APC 16/188 only.

**APC 16/186 MINUTES OF 14 SEPTEMBER 2016 MEETING** – approved.

**APC 16/187 MATTERS ARISING AND APC ACTION PLAN**

187.1

NICE TA's (July 2016)

Not applicable for use at BHNFT: -

- TA259 updated (from June 2012) - Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen
- TA387 updated - Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
- TA400 - Nivolumab in combination with ipilimumab for treating advanced melanoma

NICE TA's (August 2016)

Not applicable for use at BHNFT: -

- TA391 Re-issued (replaces TA255) Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
- TA402 Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin
- TA403 Ramucirumab for previously treated locally advanced or metastatic non-smallcell lung cancer
- TA405 Trifluridine–tipiracil for previously treated metastatic colorectal cancer

Applicable for use at BHNFT: -

- TA401 Bosutinib for previously treated chronic myeloid leukaemia

187.2

Physeptone

**Agreed actions**

- The Head of Medicines Optimisation, Barnsley CCG to amend her draft letter to Carrie Abbott to highlight that this change was not communicated with Shared Care GPs

CL

The Committee would await a response around representation from the Substance Misuse Service at future APC meetings and the physeptone issues raised by the Committee.

187.3

Action Plan – Other Areas

Continence Service Audit

**Agreed actions: -**

- The Lead Pharmacist, SWYPFT was asked to contact Sue Wing, Service Manager (cc Medical Director, Barnsley CCG) regarding the APC's concern around the professionalism of the service who appear to continue to not follow the prescribing recommendation guidelines
- The Lead Pharmacist, BHNFT to check prescribing in secondary care

SH/CL

GT

187.4

Testosterone Shared Care Guideline Re-Audit in Primary Care

Initial responses appear better than the previous audit.

**Agreed action:-**

- The full audit would be presented at the November 2016 meeting.

CA

187.5

Management of Osteoporosis and Fragility Fracture Risk

**Agreed action: -**

- The Head of Medicines Optimisation would bring data showing prescribing of Binosto® to the November meeting.

CL

Post meeting note: There are currently 5 patients being prescribed

*Binosto® in Barnsley. All 5 patients are taking a variety of oral solid dose medications. We shall continue to monitor in primary care on a quarterly basis and the next report would be presented at the February 2017 APC meeting.*

CL

187.6 Major Bleeding Incidents – admission data

Following discussion and the difficulty in being able to obtain this information, it was agreed that this action would be removed from the action plan.

NB

187.7 GLP-1 Agonist (Exenatide and Liraglutide) Traffic Light Classifications

It was agreed that this item would be on the November 2016 agenda and this would be communicated to the Associate Medical Director, SWYPFT.

NB

**APC 16/188 RESPIRATORY FORMULARY REVIEW SWITCH FROM EPIPEN TO EMERADE PENS**

Dr Kerrin, Consultant Paediatrician and Allergy Lead, BHNFT was in attendance for this item following the APC's decision to switch from Epipen® to Emerade® pens as part of the respiratory formulary review in June 2016. This was due to Epipen® short expiry dates and not having the recommended adult dose (500mg).

The Committee received Dr Kerrin's declaration of interest and there were no relevant declarations of interest to note.

Dr Kerrin provided his clinical opinion to the Committee noting that he wasn't against the switch to Emerade® pens but raised his concerns around the practicalities of switching and the need to take into account links to schools and community nurseries and ensure appropriate communication and training is provided to all stakeholders. Robust systems are currently in place and it was requested that a lead in time of 12 months (September 2017) be granted to ensure a safe and effective switch.

Dr Kerrin was thanked for attending the Committee to provide his clinical opinion.

Following Dr Kerrin's departure, the Committee accepted the concerns raised and agreed with a lead in time of 12 months for switching children to Emerade®.

It was agreed that there would be an immediate switch from Epipen® to Emerade® for adults.

**Agreed actions: -**

- BHNFT representatives to inform Dr Kerrin of the APC's decision.
- Immediate switch for adults from Epipen® to Emerade® (prescribed by brand) and community pharmacies to provide the training
- Alert to be sent out and LPC to ensure that training continues for the next 18 months
- Include alert on Scriptswitch to prescribe Emerade® by

GS/ FH

NH/CL/CA

NH/CL/CA

CA

- brand (for adults)
- The Medicines Management Pharmacist, Barnsley CCG to contact the company to obtain a supply of the Emerade® devices for GP's to allow them to provide training to patients in surgery
- The Medicines Management Team to work with Dr Kerrin and his team to coordinate the switch for children with a lead in time of 12 months to ensure that training packages are in place for all stakeholders and excellent communication links are maintained throughout

CA

NH/CL/CA

**APC 16/189 INFORMATION SUMMARY ON TICAGRELOR (BRILIQUE®▼)**

The information summary was presented by the Lead Pharmacist, BHNFT who highlighted the changes that had been made; for use in all ACS now and updated costs.

**Agreed action: -**

- The Lead Pharmacist, Barnsley CCG to follow up that all practices have a system in place such that patients are reviewed and to stop at the end of a year's treatment in line with current guidance and that 60mg doses were not being prescribed. Also to be aware that if a patient suffers another event then the year length of treatment begins again.

NH

**APC 16/190 PRESCRIBING OF ORAL MESALAZINE PREPARATIONS**

Presented by the Lead Pharmacist, BHNFT and approved by the Committee.

**APC 16/191 NEW PRODUCT APPLICATION LOG**

There were 2 new product applications yet to be considered by the Committee.

**APC 16/192 NEW PRODUCT APPLICATIONS**

192.1

Guanfacine Hydrochloride Prolonged release tablets

Presented by the Lead Pharmacist, SWYPFT who summarised the independent review, noting that this would be for use 3<sup>rd</sup> or 4<sup>th</sup> line for new patients only and in children unresponsive to or unable to take stimulants.

The Committee approved the new product application for Guanfacine Hydrochloride Prolonged release tablets with an Amber G status, pending the Shared Care being in place and clarification being provided on the responsibilities around ECGs.

**Agreed actions: -**

- The Lead Pharmacist, SWYPFT to update the existing ADHD Shared Care Guidance following the new product application approval.
- The Lead Pharmacist, SWYPFT to clarify the roles and responsibilities around ECGs within the Shared Care Guidance.

SH

SH

**APC 16/193 BARNSELYAPCREPORT@NHS.NET FEEDBACK**

The report was received and noted by the Committee.

Following a discussion around the purpose of the Barnsley APC Reporting, it was clarified that this is to bring issues to the attention of the APC Committee for information only. It was clarified that each organisation has its own incident reporting processes in place and standard organisation investigation processes would be undertaken. The APC Reporting is an additional process in place to keep the APC Committee informed of interface issues.

It was fed back that some issues are not being communicated to secondary care until the APC report is received and therefore it was clarified that incidents should be investigated by the pharmacist with the GP practice alongside submission of the APC Report.

It was identified that a number of reports sent via APC Reporting in August 2016 were not logged due to a request for further information and it was therefore stressed that all reports received, regardless of how little information is supplied must be logged on receipt.

**Agreed actions: -**

- All reports received via the Barnsley APC Reporting inbox to be logged with a request for more information if required.
- The Lead Pharmacist, Barnsley CCG and the Senior Interface Pharmacist, BHNFT to discuss investigation processes outside of the meeting.

**NB**

**NH/FH**

It was noted that a couple of APC reports would be submitted relating to the impact of the Medicines Management Dietician in primary care.

**APC 16/194**  
194.1

**NEW NICE TECHNOLOGY APPRAISALS – SEPTEMBER 2016**

Feedback from BHNFT Clinical Guidelines and Policy Group

The Lead Pharmacist, BHNFT was awaiting feedback for the applicable use of the following NICE TA's at BHNFT: -

**GT**

- TA406 Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
- TA407 Secukinumab for active ankylosing spondylitis after treatment with nonsteroidal anti-inflammatory drugs or TNF-alpha inhibitors
- TA408 Pegaspargase for treating acute lymphoblastic leukaemia
- TA409 Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion
- TA410 Talimogene laherparepvec for treating unresectable metastatic melanoma
- TA411 Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer

- TA412 Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases

194.2 Feedback from SWYPFT NICE Group (Virtual)  
The Lead Pharmacist, SWYPFT confirmed that the September 2016 NICE TA's listed above were not applicable for use at SWYPFT.

**APC 16/195 FEEDBACK FROM THE MEDICINES MANAGEMENT GROUPS**

195.1 Primary Care Quality & Cost Effective Prescribing Group

The Head of Medicines Optimisation fed back that the NICE NHS England Medicines Optimisation Dashboard for primary care was discussed. This would be analysed and looked at in further detail at how the Barnsley locality is varying from the rest of the country. Information was also available around community pharmacy services.

This would be discussed further at future Primary Care Quality & Cost Effective Prescribing Group meetings and any Barnsley wide issues would be taken forward and discussed with individual providers or brought to this Committee.

195.2 BHNFT  
No meeting had taken place.

195.3 SWYPFT Drugs & Therapeutics Committee (D&TC)  
The Lead Pharmacist, SWYPFT fed back that following email communication from the Lead Pharmacist, Barnsley CCG about another pregabalin branded generic being available, Alzain, SWYPFT had already gone 'live' with the Rewisca brand and it was confirmed that patients would remain on Rewisca.

**APC 16/196 ISSUES FOR ESCALATION TO THE QUALITY & PATIENT SAFETY COMMITTEE**

**Agreed action**

- It was agreed to escalate the Emerade® switch to the Quality & Patient Safety Committee.

**CL**

**APC 16/197 HORIZON SCANNING DOCUMENT – SEPTEMBER 2016**

The Committee agreed to classify the new products as follows on the traffic light list (TLL): -

**CA**

**Human papillomavirus 9-valent vaccine** Human papillomavirus injection in a pre-filled syringe (Gardasil 9®▼, Sanofi Pasteur MSD) – **ALREADY GREEN**

**Loxapine** 9.1 mg pre-dispensed inhalation powder (Adasuve®, Galen) – **PROVISIONAL RED**

**Bazedoxifene/ conjugated oestrogens** 0.45 mg/ 20 mg modified-release tablets (Duavive®, Pfizer) – **ALREADY PROVISIONAL GREY**

**Buprenorphine** (branded generic) 5, 10 and 20 micrograms/ h transdermal patches (Panitaz®, Dr. Reddy's Laboratories) - **GREY**

**Glycopyrronium bromide** 1 mg/5 ml oral solution (Glycopyrronium bromide, Colonis Pharma) – **PROVISIONAL RED**

**Sodium nitrite** 30 mg/mL solution for injection (Sodium nitrite, Hope Pharmaceuticals) – **PROVISIONAL RED**

**Sodium thiosulfate** 250 mg/mL solution for injection (Sodium thiosulfate, Hope Pharmaceuticals) – **PROVISIONAL RED**

**Sodium nitrite/sodium thiosulfate** 30 mg/mL solution for Injection plus 250 mg/mL solution for Injection (Nithiodote<sup>®</sup>, Hope Pharmaceuticals) – **PROVISIONAL RED**

**Levofloxacin** (generic) 5 mg/ml eye drops solution (Levofloxacin, Actavis UK) – **ALREADY AMBER G**

**Pemetrexed** (generic) 100 mg and 500 mg powder for concentrate for solution for infusion (Pemetrexed, Dr. Reddy's Laboratories) – **ALREADY RED**

**APC 16/198 MHRA DRUG SAFETY UPDATE – SEPTEMBER 2016**

The Committee received and noted the September 2016 MHRA Drug Safety Update. The summary of the alert is detailed below: -

1. Levonorgestrel-containing emergency hormonal contraception: advice on interactions with hepatic enzyme inducers and contraceptive efficacy  
Medicines or herbal remedies that induce CYP3A4 enzymes reduce blood levels of levonorgestrel, which may reduce emergency contraceptive efficacy.
2. Posaconazole (Noxafil): tablets and oral suspension are not directly interchangeable  
Switching from posaconazole oral solution to tablets has resulted in cases of dose-related toxicity, whereas switching from tablets to oral solution has resulted in under dosing and lack of efficacy.
3. Idelalisib (Zydelig ▼): updated indications and advice on minimising the risk of infection  
Updated advice for healthcare professionals is available, after conclusion of a review of the safety of idelalisib, including the risk of infection.

**APC 16/199 SOUTH YORKSHIRE AREA PRESCRIBING COMMITTEE MINUTES**

The minutes from NHS Sheffield CCG (21<sup>st</sup> July 2016) and NHS Doncaster & Bassetlaw CCG (25<sup>th</sup> August 2016) were received and noted.

**APC 16/200 ANY OTHER BUSINESS**

No further items were raised.

**APC 16/201 DATE AND TIME OF THE NEXT MEETING**

The time and date of the next meeting was confirmed as Wednesday, 9<sup>th</sup> November 2016 at 12.30 pm in the Boardroom, Hilder House.